RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Although biologics are highly effective in psoriasis, they have significant effects on innate and adaptive immune systems that may negatively impact on mechanisms of cancer immunosurveillance. However, there are limited data on the risk of cancer in psoriasis patients treated with biologics. A 70 years-old male patient presented with plaque psoriasis for four years’ duration. After receiving methotrexate for nine months, guselkumab was started due to inefficacy. After two years of guselkumab therapy, he visited the otolaryngologist with the voice change and pain around the left jaw for one year. The result of laryngoscopic biopsy showed a left supraglottic squamous cell carcinoma, and there was no metastasis on additional imaging studies. He was transferred to another hospital for surgery and concurrent chemoradiation therapy, and continues guselkumab treatment. Herein, we report on a case of laryngeal cancer during guselkumab treatment in a patient with psoriasis with the review of literatures.

번역하기

참고문헌 (Reference)

1 Haynes K, "Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases" 65 : 48-58, 2013

2 Patel S, "The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics : case report and review of the literature" 55 : 487-493, 2016

3 Dommasch ED, "The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease : a systematic review and meta-analysis of randomized controlled trials" 64 : 1035-1050, 2011

4 Chiesa Fuxench ZC, "The risk of cancer in patients with psoriasis : a population-based cohort study in the health improvement network" 152 : 282-290, 2016

5 van de Kerkhof PC, "Secukinumab Secukinumab long-term safety experience : A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis" 75 : 83-98, 2016

6 Armstrong A, "Safety of Ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis : results from greater than 17, 000 patient-years of exposure" 10 : 133-150, 2020

7 Lee JW, "Risk of malignancy in patients with psoriasis : a 15-year nationwide populationbased prospective cohort study in Korea" 33 : 2296-2304, 2019

8 Richard MA, "Psoriasis, cardiovascular events, cancer risk and alcohol use : evidence-based recommendations based on systematic review and expert opinion" 27 : 2-11, 2013

9 Kaushik SB, "Psoriasis : Which therapy for which patient : Psoriasis comorbidities and preferred systemic agents" 80 : 27-40, 2019

10 Reich K, "Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3Study" 21 : 881-890, 2020